VIA EDGAR
July 9, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Daniel Crawford
| RE: | FibroGen, Inc. |
| Registration Statement on Form S-3 |
| File No. 333-280597 |
Dear Mr. Crawford:
FibroGen, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on July 10, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes John T. McKenna of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with John T. McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059.
| Very truly yours,
| ||
| FIBROGEN, INC. | ||
| By: | /S/ THANE WETTIG | |
| Name: | Thane Wettig | |
| Title: | Chief Executive Officer | |
| cc: | Michael Lowenstein, FibroGen, Inc. |
| John T. McKenna, Cooley LLP |
FibroGen, Inc.
409 Illinois Street
San Francisco, California 94158